Cogent Biosciences Inc. shares COGT fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine potential competitors, in analysts’ view. In a trial of bezuclastinib in patients with nonadvanced systemic mastocytosis, a rare blood disorder in which too many mast cells build up in the body, everyone treated with the therapy achieved at least 50% improvement in all relevant biomarker measures, Cogent said Friday at the American Society of Hematology annual meeting in San Diego. But the results failed to clearly…
To read the full article please click HERE
Credit: Source link